stockrow
Saturday 7 November 2026
Export RCKT’s income statement to Excel — free account
Rocket Pharmaceuticals, Inc.
RCKT Healthcare Biotechnology
- EPS
- +275.8%
- Free cash flow
- +19.2%
- Total debt
- −0.25%
Quarter to June 2026, against a year earlier
2.39
0.05
−2.05%
Follow RCKT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 11 | 29 | +407.9% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (8) | (20) | (75) | (77) | (140) | (169) | (222) | (246) | (259) | (223) | (9) | +45.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (20) | (75) | (77) | (140) | (169) | (222) | (246) | (259) | (223) | (17) | +45.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1.11) | (2.88) | (1.89) | (1.58) | (2.52) | (2.67) | (3.26) | (2.92) | (2.73) | (2.01) | (0.16) | +6.8% | ||||||
| Cash flow | (0.81) | (2.35) | (1.37) | (1.32) | (1.35) | (1.92) | (2.61) | (2.32) | (2.21) | (1.71) | (1.51) | +8.7% | ||||||
| Capex | (0.05) | (0.11) | (0.04) | (0.47) | (0.37) | (0.12) | (0.12) | (0.20) | (0.06) | 0.00 | 0.00 | (24.3%) | ||||||
| Free cash flow | (0.85) | (2.46) | (1.40) | (1.79) | (1.72) | (2.04) | (2.74) | (2.52) | (2.27) | (1.71) | (1.51) | +8.0% | ||||||
| Book value | 10.71 | 2.28 | 4.93 | 6.27 | 9.09 | 7.19 | 7.19 | 5.86 | 4.89 | 2.49 | 3.27 | (14.9%) | ||||||
| Shares, m | 7 | 7 | 39 | 49 | 55 | 63 | 68 | 84 | 95 | 111 | 112 | +36.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (16) | (54) | (65) | (75) | (121) | (178) | (195) | (210) | (190) | (170) | +48.2% | |||||
| Capex | 0 | (1) | (1) | (23) | (21) | (8) | (8) | (16) | (6) | 0 | 0 | +3.1% | ||||||
| Free cash flow | (6) | (17) | (55) | (88) | (95) | (129) | (186) | (211) | (216) | (190) | (170) | +47.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 121 | 14 | 194 | 289 | 455 | 370 | 325 | 330 | 337 | 163 | 258 | +3.3% | |||||
| Net debt | (78) | (18) | (164) | (258) | (424) | (370) | (337) | (354) | (353) | (170) | (264) | +9.1% | ||||||
| Shareholders’ equity | 73 | 16 | 194 | 307 | 504 | 455 | 490 | 493 | 463 | 277 | 369 | +16.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (6.23) | (26.14) | (54.90) | (24.79) | (29.02) | (31.08) | (42.31) | (43.93) | (47.30) | (52.00) | (4.09) | (45.8) pt | |||||
| ROIC | 0.00 | 0.00 | (149.47) | (96.76) | (105.28) | (122.79) | (91.91) | (116.96) | (154.83) | (134.54) | (114.71) | (134.5) pt | ||||||
| ROE | (8.32) | (82.92) | (88.66) | (30.83) | (34.46) | (35.29) | (46.98) | (50.01) | (54.14) | (60.27) | (4.77) | (52.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 24 | 20 | 33 | 57 | 91 | 151 | 240 | 268 | 299 | 202 | — | +26.7% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Rocket Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NAUT Nautilus Biotechnology, Inc. | $273.9M | — (loss-making) | — | — | n/m | −28.59% (below 0%: shrinking) | 89.74% | (7,152.56%) | Compare |
| IPSC Century Therapeutics, Inc. | $273.4M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| TTRX Turn Therapeutics Inc. | $273.0M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| VOGX Vogenx Inc | $270.8M | — | — | — | n/m | — | — | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $267.5M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RCKT Rocket Pharmaceuticals, Inc. | $267.3M | — (loss-making) | — | — | n/m | +19.16% (above 0%: growing) | 0.00% | 0.00% | |
| ARCT Arcturus Therapeutics Holdings Inc. | $266.0M | — (loss-making) | — (loss-making) | +6.68% (above 0%: growing) | n/m | +59.86% (above 0%: growing) | 100.00% | (50.20%) | Compare |
| SPRY ARS Pharmaceuticals, Inc. | $263.5M | — (loss-making) | — (loss-making) | +16.03% (above 0%: growing) | n/m | +36.52% (above 0%: growing) | 0.00% | (90.62%) | Compare |
| QTTB Q32 Bio Inc. | $263.5M | 3.1× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $269.2M | — | — | +6.68% | — | +26.66% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 6 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.51m | (327.60k) | 17.94 |
| 2024 | 6.84m | (1.67m) | 64.23 |
| 2023 | 8.01m | 12.37m | 153.14 |
Ownership
Directors and executive officers, together
21.30%
Roderick Wong, M.D.
16.90%
RTW Investments, LP
16.70%
The Vanguard Group
7.80%
Blackrock, Inc.
5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement